Details for New Drug Application (NDA): 021991
The generic ingredient in ZOLINZA is vorinostat. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the vorinostat profile page.
Summary for 021991
| Tradename: | ZOLINZA |
| Applicant: | Msd Sub Merck |
| Ingredient: | vorinostat |
| Patents: | 3 |
Pharmacology for NDA: 021991
| Mechanism of Action | Histone Deacetylase Inhibitors |
Suppliers and Packaging for NDA: 021991
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| ZOLINZA | vorinostat | CAPSULE;ORAL | 021991 | NDA | Merck Sharp & Dohme LLC | 0006-0568 | 0006-0568-40 | 120 CAPSULE in 1 BOTTLE (0006-0568-40) |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 100MG | ||||
| Approval Date: | Oct 6, 2006 | TE: | RLD: | Yes | |||||
| Patent: | 7,456,219 | Patent Expiration: | Mar 11, 2027 | Product Flag? | Substance Flag? | Y | Delist Request? | ||
| Patent: | 8,093,295 | Patent Expiration: | May 16, 2026 | Product Flag? | Y | Substance Flag? | Delist Request? | ||
| Patent: | 8,450,372 | Patent Expiration: | Mar 18, 2028 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | TREATMENT OF CUTANEOUS MANIFESTATIONS IN PATIENTS WITH CUTANEOUS T-CELL LYMPHOMA (CTCL) | ||||||||
Expired US Patents for NDA 021991
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | 8,093,295 | ⤷ Start Trial |
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | 6,087,367 | ⤷ Start Trial |
| Msd Sub Merck | ZOLINZA | vorinostat | CAPSULE;ORAL | 021991-001 | Oct 6, 2006 | 7,732,490 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription
